AbbVie and Genmab reported that Epkinly failed to extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL) patients who had received at least one prior therapy. The companies said the study did not meet its primary endpoint, a setback for the antibody‑drug conjugate in a high‑need indication. The result will influence development prioritization and regulatory timelines for the asset and could prompt reassessment of combination strategies or patient selection. Sponsors are reviewing full datasets to determine next steps.